ARQT vs CRL
Arcutis Biotherapeutics, Inc. vs Charles River Laboratories — AI-powered side-by-side comparison
ARQT
Arcutis Biotherapeutics, Inc.
70
Buy
VS
CRL
Charles River Laboratories
61
Buy
| Metric | ARQT | CRL |
|---|
| AI Score |
70
|
61
|
| Price |
$24.85
|
$297.55
|
| P/E Ratio |
112.23×
|
-61.69×
|
| ROE |
-8.5%
|
-4.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
32.2%
|
| Debt / Equity |
0.52×
|
1.07×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
33.0
|
79.8
|
| Beta |
1.526
|
1.376
|
| Expected Upside |
+2.6%
|
+1.4%
|
AI Committee View
Current Innellis committee reasoning for ARQT versus CRL.
ARQT leads by 9 points.
ARQT scores 70/100 (Buy) versus CRL at 61/100 (Buy).
ARQT Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- News sentiment is positive (+0.80 across 5 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
CRL Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 5 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — bollinger bandwidth of 35.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 80 is in overbought territory — Technical
- Weekly RSI at 87 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 35.8% signals elevated volatility — Risk